Holen Sie sich die Stockscreener-App
2.40
2.83%
-0.07
Handel nachbörslich:
2.35
-0.05
-2.08%
Allogene Therapeutics Inc Aktie (ALLO) Neueste Nachrichten
This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision - AOL.com
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4 - TradingView
El Pollo Loco Posts Upbeat Q4 Results, Joins Kyivstar Group, American Public Education And Other Big Stocks Moving Higher On Friday - Benzinga
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 Earnings Call Transcript - Insider Monkey
Allogene Therapeutics (ALLO) Projects Key Milestones for 2026 - GuruFocus
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update - Sahm
Allogene Therapeutics 2025 Annual Report: Advancing Allogeneic CAR T Cell Therapies for Cancer and Autoimmune Diseases - Minichart
Allogene Therapeutics Inc (ALLO) Q4 2025 Earnings Call Highlight - GuruFocus
Allogene Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Allogene Therapeutics beats Q4 2025 EPS forecast By Investing.com - Investing.com India
Earnings call transcript: Allogene Therapeutics beats Q4 2025 EPS forecast - Investing.com South Africa
Rate Cut: Will Allogene Therapeutics Inc benefit from geopolitical trends2026 Drop Watch & Weekly Momentum Picks - baoquankhu1.vn
Allogene (ALLO) Q4 2025 Earnings Call Transcript - The Globe and Mail
Allogene Therapeutics Inc (NASDAQ:ALLO) Reports Narrower-Than-Expected Q4 Loss, Highlights Key 2026 Clinical Catalysts - ChartMill
Allogene Therapeutics: Fourth Quarter Earnings Overview - Bitget
Allogene Therapeutics 2025 10-K: Net loss $190.9M, EPS $(0.87); runway into Q1 2028 - TradingView
Allogene Therapeutics: Q4 Earnings Snapshot - WWLTV.com
Allogene (NASDAQ: ALLO) details 2025 loss, pipeline data milestones and cash runway - Stock Titan
Cancer and autoimmune push: inside Allogene’s 2026 CAR T trials - Stock Titan
Allogene Therapeutics advances ALLO-329 using Dagger technology to target autoimmune disease - Traders Union
Aug Shorts: What are the future prospects of Allogene Therapeutics IncAnalyst Downgrade & Entry Point Confirmation Alerts - baoquankhu1.vn
Allogene Therapeutics Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
Take the Zacks Approach to Beat the Markets: Starbucks, Amgen, Allogene in Focus - TradingView
Allogene extends cash runway into 2027 while prioritizing ALPHA3 and clinical momentum - MSN
Allogene Therapeutics (ALLO) Expected to Announce Earnings on Thursday - MarketBeat
Insider Selling: Allogene Therapeutics (NASDAQ:ALLO) SVP Sells 7,132 Shares of Stock - MarketBeat
Allogene Therapeutics Teases April ALPHA3 Futility Data, Details Autoimmune CAR-T Program at TD Cowen - Yahoo Finance
Allogene at TD Cowen Conference: Strategic Cell Therapy Insights By Investing.com - Investing.com Canada
ALLO: Key clinical milestones and manufacturing advances position allogeneic cell therapy for broad impact - TradingView
Allogene Therapeutics (NASDAQ: ALLO) files Form 144 for 7,132 RSU shares - Stock Titan
Allogene Therapeutics signals breakthrough hope for severe autoimmune disease patients - Traders Union
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update - GlobeNewswire
Cancer CAR T firm Allogene sets March 12 call on 2025 results - Stock Titan
Ideas Watch: Will Allogene Therapeutics Inc stock hit new highs in YEARMarket Trend Report & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
ALLO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Primecap Management Co. CA Has $8.78 Million Stock Position in Allogene Therapeutics, Inc. $ALLO - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Allogene Therapeutics (NASDAQ:ALLO) Reaches New 1-Year HighHere's What Happened - MarketBeat
FOMO Trade: Is Allogene Therapeutics Inc.’s ROE strong enoughGold Moves & Weekly Breakout Watchlists - mfd.ru
Allogene Therapeutics (NASDAQ:ALLO) Shares Up 10.3%Should You Buy? - MarketBeat
Allogene Therapeutics2026 Funding Rounds & List of Investors - Tracxn
Allogene Therapeutics, Inc. $ALLO Shares Acquired by Aberdeen Group plc - MarketBeat
Allogene Therapeutics (NASDAQ:ALLO) Raised to "Hold" at Wall Street Zen - MarketBeat
Treasury Yields: Whats the fair value of Blend Labs Inc stockJuly 2025 Momentum & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Allogene Therapeutics Faces Financial Challenges Despite Industry Moves - StocksToTrade
Allogene Therapeutics Teases April ALPHA3 Data as cema-cel Targets MRD+ LBCL in Remission - Yahoo Finance
MSN Money - MSN
ALLO: ALPHA-3 aims for a 25%-30% MRD clearance improvement in lymphoma, with pivotal data due in April - TradingView
Arie Belldegrun details 5.8% Allogene (ALLO) stake via multiple entities - Stock Titan
Allogene Therapeutics unveils plans for Virtual Oncology Summit - Traders Union
Atomera Among 3 Promising Penny Stocks - simplywall.st
Will Allogene Therapeutics Inc. stock outperform value stocks2025 Price Targets & Weekly Watchlist for Hot Stocks - mfd.ru
Allogene Therapeutics (NASDAQ:ALLO) Cut to "Sell" at Wall Street Zen - MarketBeat
Will Allogene Therapeutics Inc. benefit from geopolitical trendsQuarterly Portfolio Report & Fast Entry Momentum Alerts - mfd.ru
ALLO PE Ratio & Valuation, Is ALLO Overvalued - Intellectia AI
Follicular Lymphoma Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsights | AstraZeneca, InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Biologics, Xynomic - Barchart.com
Aug Selloffs: Is Bank of Montreal on track to beat earningsPortfolio Risk Summary & Detailed Earnings Play Alerts - baoquankhu1.vn
Dr. Chang (NASDAQ: ALLO) discloses 5.2% Allogene ownership stake - Stock Titan
Will Allogene Therapeutics Inc. outperform small cap indexesEarnings Trend Report & AI Powered Trade Plan Recommendations - mfd.ru
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year? - Yahoo Finance
Why Allogene Therapeutics Inc. stock could see breakout soonTreasury Yields & Stock Portfolio Risk Management - mfd.ru
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):